Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Acquisitions & Divestments (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Change in Acquisitions & Divestments for 11 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments changed N/A to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 29.79% year-over-year, with the annual reading at $3.4 million for FY2025, 29.79% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $1.6 million at BeOne Medicines, down from $1.8 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $1.1 billion in Q1 2021, with the low at -$10000.0 in Q4 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $333.4 million, with a median of $211.2 million recorded in 2022.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 100.0% in 2021, then surged 2112300.0% in 2022.
  • Over 5 years, Change in Acquisitions & Divestments stood at -$10000.0 in 2021, then soared by 2112300.0% to $211.2 million in 2022, then tumbled by 49.95% to $105.7 million in 2023, then tumbled by 97.49% to $2.7 million in 2024, then plummeted by 38.0% to $1.6 million in 2025.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $1.6 million, $1.8 million, and $2.7 million for Q4 2025, Q1 2025, and Q1 2024 respectively.